US SB637 | 2017-2018 | 115th Congress
Status
Spectrum: Partisan Bill (Democrat 5-0)
Status: Introduced on March 15 2017 - 25% progression, died in committee
Action: 2017-03-15 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 15 2017 - 25% progression, died in committee
Action: 2017-03-15 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 This bill amends title XI (General Provisions) of the Social Security Act (SSAct) to require the public disclosure of certain information provided to the Department of Health and Human Services (HHS) by a pharmacy benefit manager (PBM) that contracts with: (1) a prescription drug plan (PDP) under Medicare or Medicare Advantage (MA), or (2) a qualified health benefits plan offered through an exchange established under the Patient Protection and Affordable Care Act. Specifically, HHS must publish on its website, with respect to each PBM, information regarding: (1) the amount and type of rebates and discounts negotiated by the PBM and the extent to which these rebates and discounts are passed on to the plan sponsor, and (2) the difference between the amount paid by the plan sponsor to the PBM and the amount paid by the PBM to pharmacies. As a condition of participation as a contractor under Medicare or MA, a PBM must pass on to a PDP sponsor a minimum percentage, as established by HHS, of the amount of rebates and discounts negotiated by the PBM that are attributable to patient utilization under the plan. The bill also amends title XVIII (Medicare) of the SSAct to modify requirements regarding enrollees' access to negotiated drug prices. Current law requires a PDP sponsor to provide enrollees in Medicare or MA with access to negotiated drug prices that account for rebates and discounts. The bill requires that, with respect to a covered drug, a negotiated price (or, if necessary, an approximate negotiated price) be provided at the point of sale.
Title
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Sponsors
Sen. Ron Wyden [D-OR] | Sen. Sherrod Brown [D-OH] | Sen. Heidi Heitkamp [D-ND] | Sen. Jon Tester [D-MT] |
Sen. Thomas Carper [D-DE] |
History
Date | Chamber | Action |
---|---|---|
2017-03-15 | Senate | Read twice and referred to the Committee on Finance. |
Subjects
Government information and archives
Health
Health care costs and insurance
Inflation and prices
Medicare
Prescription drugs
Health
Health care costs and insurance
Inflation and prices
Medicare
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/115th-congress/senate-bill/637/all-info |
Text | https://www.congress.gov/115/bills/s637/BILLS-115s637is.pdf |